US20060258655A1 - Crystalline forms of linezolid intermediate - Google Patents

Crystalline forms of linezolid intermediate Download PDF

Info

Publication number
US20060258655A1
US20060258655A1 US11/362,312 US36231206A US2006258655A1 US 20060258655 A1 US20060258655 A1 US 20060258655A1 US 36231206 A US36231206 A US 36231206A US 2006258655 A1 US2006258655 A1 US 2006258655A1
Authority
US
United States
Prior art keywords
oxazolidinyl
morpholinyl
oxo
fluorophenyl
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/362,312
Inventor
Tamas Koltai
Tamar Nidam
Viviana Braude
Serguei Fine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/362,312 priority Critical patent/US20060258655A1/en
Assigned to TEVA PHARMACEUTICALS USA, INC. reassignment TEVA PHARMACEUTICALS USA, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TEVA PHARMACEUTICAL INDUSTRIES LTD.
Assigned to TEVA PHARMACEUTICAL INDUSTRIES LTD. reassignment TEVA PHARMACEUTICAL INDUSTRIES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FINE, SERGUEI, KOLTAI, TAMAS, BRAUDE, VIVIANA, NIDAM, TAMAR
Publication of US20060258655A1 publication Critical patent/US20060258655A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to the solid state chemistry of the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine.
  • Linezolid [(S)—N-[[3-(3-Fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] is an antimicrobial agent.
  • Linezolid is an oxazolidinone, having the empirical formula C 16 H 20 FN 3 O 4 and the following structure (I):
  • Linezolid is described in The Merck Index (13th edition, Monograph number: 05526, CAS Registry Number: 165800-03-3) as white crystals, with a melting point of 181.5-182.5°.
  • Linezolid, as well as a process for its preparation, is disclosed in U.S. Pat. No. 5,688,792 (Example 5), European Patent No. 717738, Israeli Patent No. 110,802, Canadian Patent No. 2,168,560, and International Patent Publication WO 95/07271.
  • Crystalline Form III linezolid is disclosed in U.S. Pat. No. 6,559,305.
  • Linezolid is marketed in the United States by Pfizer, Inc. as an injection, tablets, and oral suspension under the name ZYVOX®. Its main indications are nosocomial pneumonia, skin and skin-structure infections, and vancomycin-resistant Enterococcus faecium infections.
  • the intermediate azide R—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) is reduced to its corresponding amine, S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) in the solvent ethyl acetate by hydrogenation using hydrogen gas and a palladium/carbon catalyst.
  • These reaction conditions lead to the production of an undesirable level of reaction by-products, and, following the acetylation of the intermediate amine (II) to linezolid (I), to undesirably high levels of bis-linezolid (IV).
  • the present invention relates to the solid state physical properties of an intermediate of linezolid, S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II). These properties can be influenced by controlling the conditions under which S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) is obtained in solid form.
  • One important solid state property is its rate of dissolution in aqueous fluid or its behavior on compaction and its storage stability.
  • polymorphic form may give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others.
  • TGA thermogravimetric analysis
  • DSC differential scanning calorimetry
  • a particular polymorphic form may also give rise to distinct spectroscopic properties that may be detectable by powder X-ray crystallography, solid state 13 C NMR spectrometry and infrared spectrometry.
  • the present invention is based on the finding that the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) can be obtained in at least three different crystalline forms: Form A, Form B, and Form C.
  • the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form A, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 13.2 ⁇ 0.2, 14.8 ⁇ 0.2, 15.1 ⁇ 0.2, and 25.0 ⁇ 0.2 degrees 2 theta or substantially as indicated in FIG. 1 .
  • PXRD powder X-ray diffraction
  • the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form B, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 15.6 ⁇ 0.2, 19.2 ⁇ 0.2, 22.5 ⁇ 0.2, and 24.3 ⁇ 0.2 degrees 2 theta or substantially as indicated in FIG. 2 .
  • PXRD powder X-ray diffraction
  • the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form C, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 5.8 ⁇ 0.2, 11.5 ⁇ 0.2, 19.6 ⁇ 0.2, and 26.3 ⁇ 0.2 degrees 2 theta or substantially as indicated in FIG. 3 .
  • PXRD powder X-ray diffraction
  • FIG. 1 shows the powder X-ray diffractogram of linezolid intermediate amine (II) Form A.
  • FIG. 2 shows the powder X-ray diffractogram of linezolid intermediate amine (II) Form B.
  • FIG. 3 shows the powder X-ray diffractogram of linezolid intermediate amine (II) Form C.
  • the present invention is based on the finding that the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) can be obtained in at least three different crystalline forms: Form A, Form B, and Form C.
  • the present invention provides novel solid crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II), referred to herein as Form A, Form B, and Form C.
  • the crystalline Forms A, B, and C may be distinguished by their respective powder X-ray diffraction (PXRD) patterns.
  • the crystalline forms have characteristic PXRD peak positions in the range of 2-40 degrees two theta. Crystalline Forms A, B, and C can be identified by these characteristic peak positions and the identity and quantify of their crystalline impurities can also be determined.
  • the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form A, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 13.2 ⁇ 0.2, 14.8 ⁇ 0.2, 15.1 ⁇ 0.2, and 25.0 ⁇ 0.2 degrees 2 theta.
  • Form A maybe further characterized by PXRD peaks at 3.05 +0.2, 16.1 ⁇ 0.2, 17.9 ⁇ 0.2, 19.3 ⁇ 0.2, and 23.0 ⁇ 0.2 degrees 2 theta, substantially as depicted in FIG. 1 .
  • the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form B, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 15.6 ⁇ 0.2, 19.2 ⁇ 0.2, 22.5 ⁇ 0.2, and 24.3 ⁇ 0.2 degrees 2 theta.
  • Form B may be further characterized by PXRD peaks at 7.2 ⁇ 0.2, 14.6 ⁇ 0.2, 16.5 ⁇ 0.2, 20.1 ⁇ 0.2, and 23.0 ⁇ 0.2 degrees 2 theta, substantially as depicted in FIG. 2 .
  • the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form C, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 5.8 ⁇ 0.2, 11.5 ⁇ 0.2, 19.6 ⁇ 0.2, and 26.3 ⁇ 0.2 degrees 2 theta.
  • Form C may be further characterized by PXRD peaks at 13.2 ⁇ 0.2, 20.4 ⁇ 0.2, 21.6 ⁇ 0.2, 22.3 ⁇ 0.2, 23.0 ⁇ 0.2, and 23.8 ⁇ 0.2 degrees 2 theta, substantially as depicted in FIG. 3 .
  • the crystalline Forms A, B, and C of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of the present invention may be substantially pure with respect to other crystalline forms, i.e., the novel forms contain less than about 10%, preferably less than about 5%, and even more preferably less than about 1% (by weight) of other crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II).
  • the novel crystalline forms contain less than about 10%, preferably less than about 5%, and even more preferably less than about 1% (by weight) of amorphous S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II).
  • the present invention is not intended to encompass true solutions of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) wherein the crystal structure of the novel crystalline Forms A, B, and C and the properties that distinguish the novel crystalline forms of the present invention are lost.
  • the preferred form of the present invention is that of solid forms of crystalline Forms A, B, and C.
  • the use of the novel forms to prepare solutions is considered to be within the contemplation of the invention.
  • Powder X-ray diffraction data were obtained by methods known in the art using a SCINTAG® powder X-ray diffractometer model X'TRA® equipped with a solid state detector. Copper radiation of 1.5418 ⁇ was used. A round aluminum sample holder with round zero background quartz plate was used, with cavity of 25(diameter)* 0.5(depth) mm. The obtained characteristic peaks were in the range of 2-40 degrees two theta.

Abstract

The present invention relates to novel crystalline forms of the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine referred to herein as Form A, Form B, and Form C.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of provisional application Ser. Nos. 60/656,778, filed Feb. 24, 2005, 60/656,646, filed Feb. 24, 2005, and 60/690,822, filed Jun. 14, 2005, which are incorporated herein by reference.
    • FIELD OF THE INVENTION
  • The present invention relates to the solid state chemistry of the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine.
    • BACKGROUND OF THE INVENTION
  • Linezolid [(S)—N-[[3-(3-Fluoro-4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide] is an antimicrobial agent. Linezolid is an oxazolidinone, having the empirical formula C16H20FN3O4 and the following structure (I):
    Figure US20060258655A1-20061116-C00001
  • Linezolid is described in The Merck Index (13th edition, Monograph number: 05526, CAS Registry Number: 165800-03-3) as white crystals, with a melting point of 181.5-182.5°. Linezolid, as well as a process for its preparation, is disclosed in U.S. Pat. No. 5,688,792 (Example 5), European Patent No. 717738, Israeli Patent No. 110,802, Canadian Patent No. 2,168,560, and International Patent Publication WO 95/07271.
  • Crystalline Form III linezolid is disclosed in U.S. Pat. No. 6,559,305.
  • Linezolid is marketed in the United States by Pfizer, Inc. as an injection, tablets, and oral suspension under the name ZYVOX®. Its main indications are nosocomial pneumonia, skin and skin-structure infections, and vancomycin-resistant Enterococcus faecium infections.
  • U.S. Pat. No. 5,688,792 claims linezolid and its use for the treatment of microbial infections. This patent also discloses, but does not claim, the following method of preparation:
    Figure US20060258655A1-20061116-C00002
  • This method of preparation was also disclosed in Bricker, et al., J. Med. Chem., 39 673-679 (1996), where it was stated that the above route avoids the use of phosgene to make the carbamate precursor of the oxazolidinone ring. The authors also disclose that the use of NaN3 can be avoided by using potassium phthalimide, followed by deblocking of the phthalimide with aqueous methyl amine.
  • In the above-described synthesis, the intermediate amine, S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II)
    Figure US20060258655A1-20061116-C00003
    is reacted without isolation with acetic anhydride as an oily product, or in solution, to produce the acetamide, linezolid (I). This is followed by procedures for isolating the linezolid such as those described in U.S. Pat. No. 5,688,792, at col. 15, 11. 22-28 (chromatography and separation of the desired fraction, followed by evaporation and trituration of the product to obtain pure linezolid).
  • In the above-described syntheses, the intermediate azide R—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III)
    Figure US20060258655A1-20061116-C00004
    is reduced to its corresponding amine, S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) in the solvent ethyl acetate by hydrogenation using hydrogen gas and a palladium/carbon catalyst. These reaction conditions lead to the production of an undesirable level of reaction by-products, and, following the acetylation of the intermediate amine (II) to linezolid (I), to undesirably high levels of bis-linezolid (IV).
    Figure US20060258655A1-20061116-C00005
  • The present invention relates to the solid state physical properties of an intermediate of linezolid, S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II). These properties can be influenced by controlling the conditions under which S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) is obtained in solid form. One important solid state property is its rate of dissolution in aqueous fluid or its behavior on compaction and its storage stability.
  • These practical physical characteristics are influenced by the conformation and orientation of molecules in the unit cell, which defines a particular polymorphic form of a substance. The polymorphic form may give rise to thermal behavior different from that of the amorphous material or another polymorphic form. Thermal behavior is measured in the laboratory by such techniques as capillary melting point, thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) and can be used to distinguish some polymorphic forms from others. A particular polymorphic form may also give rise to distinct spectroscopic properties that may be detectable by powder X-ray crystallography, solid state 13C NMR spectrometry and infrared spectrometry.
    • SUMMARY OF THE INVENTION
  • The present invention is based on the finding that the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) can be obtained in at least three different crystalline forms: Form A, Form B, and Form C.
  • In one embodiment, the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form A, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 13.2±0.2, 14.8±0.2, 15.1±0.2, and 25.0±0.2 degrees 2 theta or substantially as indicated in FIG. 1.
  • In one embodiment, the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form B, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 15.6±0.2, 19.2±0.2, 22.5±0.2, and 24.3±0.2 degrees 2 theta or substantially as indicated in FIG. 2.
  • In one embodiment, the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form C, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 5.8±0.2, 11.5±0.2, 19.6±0.2, and 26.3±0.2 degrees 2 theta or substantially as indicated in FIG. 3.
  • These new crystalline forms were found to be chemically pure (by HPLC) and found to be a single crystalline form (by PXRD). Each form contains less than about 5% of other crystalline forms of intermediate amine (II) and contains less than about 5% of the intermediate azide (III).
    • FIGURES
  • FIG. 1 shows the powder X-ray diffractogram of linezolid intermediate amine (II) Form A.
  • FIG. 2 shows the powder X-ray diffractogram of linezolid intermediate amine (II) Form B.
  • FIG. 3 shows the powder X-ray diffractogram of linezolid intermediate amine (II) Form C.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention is based on the finding that the linezolid intermediate S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) can be obtained in at least three different crystalline forms: Form A, Form B, and Form C. Thus, the present invention provides novel solid crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II), referred to herein as Form A, Form B, and Form C.
  • The crystalline Forms A, B, and C may be distinguished by their respective powder X-ray diffraction (PXRD) patterns. The crystalline forms have characteristic PXRD peak positions in the range of 2-40 degrees two theta. Crystalline Forms A, B, and C can be identified by these characteristic peak positions and the identity and quantify of their crystalline impurities can also be determined.
  • In one embodiment, the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form A, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 13.2±0.2, 14.8±0.2, 15.1±0.2, and 25.0±0.2 degrees 2 theta. Form A maybe further characterized by PXRD peaks at 3.05 +0.2, 16.1±0.2, 17.9±0.2, 19.3±0.2, and 23.0±0.2 degrees 2 theta, substantially as depicted in FIG. 1.
  • In one embodiment, the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form B, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 15.6±0.2, 19.2±0.2, 22.5±0.2, and 24.3±0.2 degrees 2 theta. Form B may be further characterized by PXRD peaks at 7.2±0.2, 14.6±0.2, 16.5±0.2, 20.1±0.2, and 23.0±0.2 degrees 2 theta, substantially as depicted in FIG. 2.
  • In one embodiment, the present invention provides a crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) referred to herein as Form C, characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 5.8±0.2, 11.5±0.2, 19.6±0.2, and 26.3±0.2 degrees 2 theta. Form C may be further characterized by PXRD peaks at 13.2±0.2, 20.4±0.2, 21.6±0.2, 22.3±0.2, 23.0±0.2, and 23.8±0.2 degrees 2 theta, substantially as depicted in FIG. 3.
  • The characteristic PXRD peaks of the novel crystalline forms of the intermediate amine (II) are shown in Table 1, with the most characteristic peaks indicated in bold.
    TABLE 1
    Characteristic PXRD peaks in degrees 2 theta
    Form A Form B Form C
    3.0 7.2 5.8
    13.2 14.6 11.5
    14.8 15.6 13.2
    15.1 16.5 19.6
    16.1 19.2 20.4
    17.9 20.1 21.6
    19.3 22.5 22.3
    23.0 23.0 23.0
    25.0 24.3 23.8
    26.3
  • The crystalline Forms A, B, and C of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of the present invention may be substantially pure with respect to other crystalline forms, i.e., the novel forms contain less than about 10%, preferably less than about 5%, and even more preferably less than about 1% (by weight) of other crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II). In certain embodiments, the novel crystalline forms contain less than about 10%, preferably less than about 5%, and even more preferably less than about 1% (by weight) of amorphous S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II).
  • The present invention is not intended to encompass true solutions of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) wherein the crystal structure of the novel crystalline Forms A, B, and C and the properties that distinguish the novel crystalline forms of the present invention are lost. Thus, the preferred form of the present invention is that of solid forms of crystalline Forms A, B, and C. However, the use of the novel forms to prepare solutions (e.g., so as to provide a material for conversion into linezolid (I)) is considered to be within the contemplation of the invention.
  • Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the preparation of the composition and methods of use of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
  • HPLC Method
  • Column Hypersil Gold 150×4.6, 5μ
  • Detection limit: 0.1%
  • Eluents: K2HPO4 0.01M: MeOH A: 80:20 B: 50:50
    TABLE 2
    Time A B Flow
    0 100 0 1.5
    15 57 43 2
    25 35 65 2

    Powder X-Ray Diffraction
  • Powder X-ray diffraction data were obtained by methods known in the art using a SCINTAG® powder X-ray diffractometer model X'TRA® equipped with a solid state detector. Copper radiation of 1.5418 Å was used. A round aluminum sample holder with round zero background quartz plate was used, with cavity of 25(diameter)* 0.5(depth) mm. The obtained characteristic peaks were in the range of 2-40 degrees two theta.
    • EXAMPLES Example 1 Preparation of Intermediate Amine (II) Crystalline Form B
  • In a 1L reactor, 6 g R—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) was charged with 150 ml ethyl acetate, followed by 0.6 g 10% Pd/C. The system was flushed 3 times with nitrogen and 3 times with hydrogen. The pressure of hydrogen was set to 1.5 atm. The reaction mixture was stirred at RT and the reaction followed by TLC or HPLC until completion. The reaction mixture was filtered through celite and the solution was evaporated to obtain 4.6 g S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) as a white solid. The crystals were analyzed by PXRD and showed a novel form of) the intermediate amine (II) (Form B, 91.7% total purity by HPLC).
    • Example 2 Preparation of Intermediate Amine (II) Crystalline Form C
  • In a 10L reactor, 150 g R—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) was charged, followed by 15 g Pd/C in 5L toluene. Finally 500 ml ammonium hydroxide was added. The system was flushed 3 times with nitrogen and 3 times with hydrogen. The pressure of hydrogen was set to 1.5 atm. The reaction mixture was stirred at RT and the reaction followed by TLC or HPLC until completion. The reaction mixture was filtered through celite. S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) precipitated on standing and/or cooling as a white solid, was filtered, and dried at 50° C. overnight. The crystals obtained were analyzed by PXRD and showed a novel form of the intermediate amine (II) (Form C, 98.6% total purity by HPLC).
    • Example 3 Preparation of Intermediate Amine (II) Crystalline Form A
  • In a three necked flask, 6.4 g R—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl azide (III) was charged, followed by 2.5 g ammonium formate, 23 ml ethanol, and 2.6 g zinc powder. The reaction mixture was stirred at RT and the reaction followed by TLC or HPLC until completion. 60 ml acetone were then added. The reaction mixture was filtered and by evaporation S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) was obtained as a solid. The crystals obtained were analyzed by PXRD and showed a novel form of the intermediate amine (II) (Form A, 96.5% total purity by HPLC).

Claims (12)

1. A crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 13.2±0.2, 14.8±0.2, 15.1±0.2, and 25.0±0.2 degrees 2 theta.
2. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 1 further characterized by PXRD peaks at 3.0±0.2, 16.1±0.2, 17.9±0.2, 19.3±0.2, and 23.0±0.2 degrees 2 theta.
3. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 1 which contains less than 5% by weight of other crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II).
4. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 1, characterized by a powder X-ray diffraction (PXRD) pattern substantially as indicated in FIG. 1.
5. A crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II), characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 15.6±0.2, 19.2±0.2, 22.5±0.2, and 24.3±0.2 degrees 2 theta.
6. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 5 further characterized by PXRD peaks at 7.2±0.2, 14.6±0.2, 16.5±0.2, 20.1±0.2, and 23.0±0.2 degrees 2 theta.
7. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 5 which contains less than 5% by weight of other crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II).
8. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 5, characterized by a powder X-ray diffraction (PXRD) pattern substantially as indicated in FIG. 2.
9. A crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II), characterized by a powder X-ray diffraction (PXRD) pattern with peaks at 5.8±0.2, 11.5±0.2, 19.6±0.2, and 26.3±0.2 degrees 2 theta.
10. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 9 further characterized by PXRD peaks at 13.2±0.2, 20.4±0.2, 21.6±0.2, 22.3±0.2, 23.0±0.2, and 23.8±0.2 degrees 2 theta.
11. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 9 which contains less than 5% by weight of other crystalline forms of S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II).
12. The crystalline S—N-(4-morpholinyl-3-fluorophenyl)-2-oxo-5-oxazolidinyl-methyl amine (II) of claim 9, characterized by a powder X-ray diffraction (PXRD) pattern substantially as indicated in FIG. 3.
US11/362,312 2005-02-24 2006-02-24 Crystalline forms of linezolid intermediate Abandoned US20060258655A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/362,312 US20060258655A1 (en) 2005-02-24 2006-02-24 Crystalline forms of linezolid intermediate

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65677805P 2005-02-24 2005-02-24
US65664605P 2005-02-24 2005-02-24
US69082205P 2005-06-14 2005-06-14
US11/362,312 US20060258655A1 (en) 2005-02-24 2006-02-24 Crystalline forms of linezolid intermediate

Publications (1)

Publication Number Publication Date
US20060258655A1 true US20060258655A1 (en) 2006-11-16

Family

ID=36498839

Family Applications (4)

Application Number Title Priority Date Filing Date
US11/361,457 Expired - Fee Related US7291614B2 (en) 2005-02-24 2006-02-23 Processes for the preparation of linezolid intermediate
US11/362,312 Abandoned US20060258655A1 (en) 2005-02-24 2006-02-24 Crystalline forms of linezolid intermediate
US11/361,509 Abandoned US20060252932A1 (en) 2005-02-24 2006-02-24 Isolated bis-linezolid, preparation thereof, and its use as a reference standard
US11/977,344 Abandoned US20080045707A1 (en) 2005-02-24 2007-10-23 Processes for the preparation of linezolid intermediate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/361,457 Expired - Fee Related US7291614B2 (en) 2005-02-24 2006-02-23 Processes for the preparation of linezolid intermediate

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/361,509 Abandoned US20060252932A1 (en) 2005-02-24 2006-02-24 Isolated bis-linezolid, preparation thereof, and its use as a reference standard
US11/977,344 Abandoned US20080045707A1 (en) 2005-02-24 2007-10-23 Processes for the preparation of linezolid intermediate

Country Status (8)

Country Link
US (4) US7291614B2 (en)
EP (3) EP1866295A2 (en)
JP (2) JP2008530028A (en)
CA (2) CA2602073A1 (en)
IL (3) IL183379A0 (en)
MX (3) MX2007010141A (en)
TW (1) TW200640886A (en)
WO (3) WO2006091731A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019632A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011114210A2 (en) 2010-03-15 2011-09-22 Jubilant Life Sciences Limited Processes for the preparation of linezolid
BR112012027901A2 (en) 2010-04-30 2015-09-08 Univ Indiana Res & Tech Corp processes for preparing linezolid
US9567307B2 (en) 2011-01-07 2017-02-14 The Regents Of The University Of California Amination of aryl alcohol derivatives
WO2013111048A1 (en) 2012-01-24 2013-08-01 Jubilant Life Sciences Limited Improved process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
US9586913B2 (en) 2013-04-25 2017-03-07 Symed Labs Limited Processes for the preparation of linezolid using novel intermediates
CA2930128A1 (en) 2013-11-15 2015-05-21 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN109265407B (en) * 2018-10-23 2020-05-29 扬子江药业集团北京海燕药业有限公司 Synthesis method of bislinezolid
CN109444294B (en) * 2018-12-27 2021-06-22 苏州莱奥生物技术有限公司 High performance liquid chromatography method for separating linezolid and chiral isomer thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US6333198B1 (en) * 1998-06-10 2001-12-25 Glaxo Wellcome, Inc. Compound and its use
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801600A (en) 1987-10-09 1989-01-31 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl cycloalkylbenzene derivatives useful as antibacterial agents
US4948801A (en) * 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
WO1993009103A1 (en) * 1991-11-01 1993-05-13 The Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (en) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
US5750717A (en) * 1994-03-02 1998-05-12 Daicel Chemical Industries, Ltd. 2-isoxazoline derivative and process for producing the same, and process for producing related derivatives from the same
JP3831954B2 (en) * 1995-05-19 2006-10-11 ダイソー株式会社 Process for producing 4-hydroxy-2-pyrrolidone
DE19827282A1 (en) * 1998-06-19 1999-12-23 Bayer Ag Process for the preparation of cycloaliphatic amines
AR027261A1 (en) 2000-02-02 2003-03-19 Upjohn Co LINEZOLID CRYSTAL FORM II
US6514529B2 (en) * 2000-03-22 2003-02-04 Pharmacia & Upjohn Company Oxazolidinone tablet formulation
YU52403A (en) * 2000-12-26 2006-03-03 Dr.Reddy's Research Foundation Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
DE60234510D1 (en) * 2001-04-16 2010-01-07 Eisai R&D Man Co Ltd 1H-INDAZONE COMPOUNDS THE JNK HEMMEN
AU2001100437A4 (en) 2001-10-03 2001-11-01 Pfizer Limited Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
AU2003224345A1 (en) * 2002-04-30 2003-11-17 Orchid Chemicals & Pharmaceuticals Antibacterial agents
WO2004026848A1 (en) 2002-09-20 2004-04-01 Lupin Limited Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
ATE442364T1 (en) 2003-10-16 2009-09-15 Symed Labs Ltd CRYSTALLINE FORM OF LINEZOLIDE
US20060111350A1 (en) * 2004-06-29 2006-05-25 Judith Aronhime Solid forms of linezolid and processes for preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US6333198B1 (en) * 1998-06-10 2001-12-25 Glaxo Wellcome, Inc. Compound and its use
US6444813B2 (en) * 2000-02-02 2002-09-03 Pharmacia & Upjohn Company Linezolid-crystal form II
US6559305B1 (en) * 2000-02-02 2003-05-06 Pharmacia & Upjohn Company Linezolid—crystal form II

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019632A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
WO2012019862A1 (en) 2010-08-11 2012-02-16 Synthon B.V. Process for making linezolid
EP2690100A1 (en) 2010-08-11 2014-01-29 Synhton B.V. Process for making linezolid
WO2014071990A1 (en) 2012-11-09 2014-05-15 Synthon Bv Process for making linezolid

Also Published As

Publication number Publication date
WO2006091848A9 (en) 2006-11-09
JP2008530144A (en) 2008-08-07
JP2008530028A (en) 2008-08-07
US20080045707A1 (en) 2008-02-21
US20060252932A1 (en) 2006-11-09
WO2006091731A2 (en) 2006-08-31
EP1866295A2 (en) 2007-12-19
IL184038A0 (en) 2007-10-31
TW200640886A (en) 2006-12-01
MX2007010136A (en) 2007-09-27
WO2006091848A2 (en) 2006-08-31
EP1861383A2 (en) 2007-12-05
CA2602073A1 (en) 2006-08-31
WO2006091731A3 (en) 2006-10-19
US7291614B2 (en) 2007-11-06
CA2588876A1 (en) 2006-08-31
IL183379A0 (en) 2007-09-20
US20070021417A1 (en) 2007-01-25
MX2007010143A (en) 2007-09-27
IL183380A0 (en) 2007-09-20
EP1853571A1 (en) 2007-11-14
MX2007010141A (en) 2007-09-27
WO2006091777A1 (en) 2006-08-31
WO2006091848A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
US20060258655A1 (en) Crystalline forms of linezolid intermediate
US11149017B2 (en) Solid state forms of apalutamide
US9630952B2 (en) Crystalline forms of afatinib di-maleate
US8394962B2 (en) Method for the preparation of dabigatran and its intermediates
US10023566B2 (en) Dasatinib salts
SK286569B6 (en) Method for the production of oxazolidinones
US20120101099A1 (en) Histone deacetylase inhibitors
CN110372562B (en) Crystal form of key intermediate of BTK kinase inhibitor and preparation method thereof
US20080269342A1 (en) Pleuromutilin Derivatives and Its Use
JPWO2007148711A1 (en) N- (3,4-disubstituted phenyl) salicylamide derivatives
US8962827B2 (en) Linezolid intermediate and method for synthesizing linezolid
JP2008508236A (en) Oxazolidinone compounds and related compositions and methods
US20060258863A1 (en) Synthesis of CCR5 antagonists
JP2014139175A (en) Therapeutic compounds
US11214547B2 (en) Crystalline Eltrombopag monoethanolamine salt form D
US20200347027A1 (en) Crystalline forms of lenalidomide
KR20230021075A (en) Forms and Compositions of Beta Adrenergic Agonists
US20090312351A1 (en) Processes for the Preparation of Alfuzosin
TWI711612B (en) Pharmaceutically acceptable salt, crystalline form of azabicyclo substituted triazole derivative and preparation method thereof
JP5077232B2 (en) Crystals of benzooxadiazole derivatives
US20170066728A1 (en) Process for the preparation of stable crystalline form-i of linezolid, substantially free of residual solvent
WO2003061552A2 (en) Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone
CN112830919B (en) Benzopiperidine derivatives as pharmaceutical agents and process for preparing them
US20240092768A1 (en) Crystal form of anti-influenza virus compound, preparation method for crystal form, and use of crystal form
US20230278977A1 (en) Stable polymorph of r-mdma hcl

Legal Events

Date Code Title Description
AS Assignment

Owner name: TEVA PHARMACEUTICAL INDUSTRIES LTD., ISRAEL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KOLTAI, TAMAS;NIDAM, TAMAR;BRAUDE, VIVIANA;AND OTHERS;REEL/FRAME:017926/0069;SIGNING DATES FROM 20060423 TO 20060518

Owner name: TEVA PHARMACEUTICALS USA, INC., PENNSYLVANIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TEVA PHARMACEUTICAL INDUSTRIES LTD.;REEL/FRAME:017926/0266

Effective date: 20060604

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION